公开(公告)号：US20140099313A1

公开(公告)日：2014-04-10

申请号：US14101145

申请日：2013-12-09

Applicant: AbbVie Inc.

Inventor： Chengbin WU ,  Richard W. DIXON ,  Jonathan P. BELK ,  Maria A. ARGIRIADI ,  Hua YING ,  Carolyn A. CUFF ,  Terry L. MELIM ,  Shankar KUMAR ,  Paul R. HINTON ,  Yan CHEN

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K45/06 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hIL-13活性有害的病症的人类受试者中。

公开(公告)号：US20170340737A1

公开(公告)日：2017-11-30

申请号：US15457264

申请日：2017-03-13

Applicant: AbbVie Inc.

Inventor： Chengbin WU ,  Richard W. DIXON ,  Jonathan P. BELK ,  Hua YING ,  Maria A. ARGIRIADI ,  Carolyn A. CUFF ,  Paul R. HINTON ,  Shankar KUMAR ,  Terry L. MELIM ,  Yan CHEN

IPC: A61K45/06 ,  C07K16/24 ,  A61K39/395 ,  C07K14/47 ,  A61K38/00

CPC classification number: A61K45/06 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.